Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat

被引:65
作者
Hartfield, AW
Moore, NA
Clifton, PG [1 ]
机构
[1] Univ Sussex, Expt Psychol Lab, Brighton BN1 9QG, E Sussex, England
[2] Eli Lilly & Co, Windlesham GU20 6PH, Surrey, England
关键词
antipsychotic; haloperidol; clozapine; olanzapine; rat; hyperphagia; microstructure;
D O I
10.1007/s00213-002-1368-8
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: Antipsychotic drugs, particularly the newer atypical compounds, have been associated with rapid weight gain in a clinical setting. However, there are few reported animal models producing reliable hyperphagia correlating with the human weight gain liability of these drugs. Objective: To compare the effects of the classic neuroleptic haloperidol with the atypical antipsychotics clozapine and olanzapine on the microstructure of ingestive behaviour in rats. Methods: Male hooded Lister rats drank a palatable high-calorie fat emulsion (10% Intralipid) during 30-min test sessions and microstructural analyses were made following administration of each drug over a range of doses. Results: Clozapine (0.3 mg/kg) and olanzapine (0.1, 0.3, 1 mg/kg) significantly increased intake, whilst haloperidol (0.05, 0.1, 0.2 mg/kg) significantly decreased drinking. No significant changes in the latency to the first lick were observed following any of the drugs tested. Median interlick intervals showed small, dose-related increases after clozapine (3.0 mg/kg), olanzapine (0.3, 1.0 mg/kg) and haloperidol (0.1, 0.2 mg/kg). Olanzapine (1.0 mg/kg) significantly elevated the number of clusters of licking (bouts of licking separated by pauses greater than 500 ms), whilst clozapine and haloperidol did not. Mean cluster size (licks per cluster) was not affected by clozapine or olanzapine, but haloperidol (0.025, 0.05, 0.1, 0.2 mg/kg) produced marked, significant decreases in cluster size. Conclusions: Clozapine and olanzapine increased fat intake whereas haloperidol did not, and this resembles the greater weight gain liability of atypical antipsychotics in humans. A delay or reduction of the post-ingestive satiety signal combined with preserved palatability appears to be the mechanism responsible for fat hyperphagia in rats treated with clozapine and olanzapine. Conversely, haloperidol leaves satiety unaffected but reduces the palatability of the fat emulsion resulting in reduced intake.
引用
收藏
页码:115 / 122
页数:8
相关论文
共 33 条
[1]  
Allison DB, 1999, AM J PSYCHIAT, V156, P1686
[2]   DIFFERENTIAL-EFFECTS OF SEROTONERGIC AND CATECHOLAMINERGIC DRUGS ON INGESTIVE BEHAVIOR [J].
ASIN, KE ;
DAVIS, JD ;
BEDNARZ, L .
PSYCHOPHARMACOLOGY, 1992, 109 (04) :415-421
[3]   EFFECTS OF LONG-TERM ADMINISTRATION OF CLOZAPINE ON BODY-WEIGHT AND FOOD-INTAKE IN RATS [J].
BAPTISTA, T ;
MATA, A ;
TENEUD, L ;
DEQUIJADA, M ;
HAN, HW ;
HERNANDEZ, L .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1993, 45 (01) :51-54
[4]   LONG-TERM ADMINISTRATION OF SOME ANTIPSYCHOTIC-DRUGS INCREASES BODY-WEIGHT AND FEEDING IN RATS - ARE D2 DOPAMINE-RECEPTORS INVOLVED [J].
BAPTISTA, T ;
PARADA, M ;
HERNANDEZ, L .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1987, 27 (03) :399-405
[5]   Body weight gain induced by antipsychotic drugs: mechanisms and management [J].
Baptista, T .
ACTA PSYCHIATRICA SCANDINAVICA, 1999, 100 (01) :3-16
[6]   Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone [J].
Basson, BR ;
Kinon, BJ ;
Taylor, CC ;
Szymanski, KA ;
Gilmore, JA ;
Tollefson, GD .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (04) :231-238
[7]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[8]  
Benvenga MJ, 1997, DRUG DEVELOP RES, V41, P48
[9]   The unhealthy lifestyle of people with schizophrenia [J].
Brown, S ;
Birtwistle, J ;
Roe, L ;
Thompson, C .
PSYCHOLOGICAL MEDICINE, 1999, 29 (03) :697-701
[10]   Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist, and d-fenfluramine on feeding patterns in the rat [J].
Clifton, PG ;
Lee, MD ;
Dourish, CT .
PSYCHOPHARMACOLOGY, 2000, 152 (03) :256-267